|
|
|
Insider
Information: |
Novo A/s |
Relationship: |
10% Owner |
City: |
Bagsvaerd |
State: |
G7 |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
43 |
|
Direct
Shares |
93,473,310 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$956,770,407 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
93,473,310 |
|
|
Total
Value |
$956,770,407 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
17
|
Stock
price went up :
|
0
|
14
|
Stock
price went down : |
2
|
3
|
|
|
|
Gain/Loss Ratio : |
-2.0
|
4.7
|
Percentage
Gain/Loss : |
-52.2%
|
353.8%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Biomimetic Therapeutics, Inc. |
BMTI |
10% Owner |
2013-03-01 |
0 |
2006-05-11 |
0 |
Premium* |
|
Iveric Bio Inc |
ISEE |
10% Owner |
2016-12-15 |
0 |
2013-09-30 |
0 |
Premium* |
|
Inogen Inc |
INGN |
10% Owner |
2021-06-02 |
2,079,320 |
|
0 |
Premium* |
|
Flexion Therapeutics Inc |
FLXN |
10% Owner |
2015-06-22 |
2,133,131 |
2014-02-18 |
0 |
Premium* |
|
Akebia Therapeutics, Inc. |
AKBA |
SEE REMARKS, 10% Owner |
2014-03-25 |
1,516,387 |
2014-03-25 |
0 |
Premium* |
|
Alder Biopharmaceuticals Inc |
ALDR |
SEE REMARKS, 10% Owner |
2014-05-13 |
3,201,183 |
2014-05-13 |
0 |
Premium* |
|
Zs Pharma, Inc. |
ZSPH |
See Remarks, 10% Owner |
2014-06-23 |
781,730 |
2014-06-23 |
0 |
Premium* |
|
Otonomy, Inc. |
OTIC |
SEE REMARKS, 10% Owner |
2014-08-19 |
2,175,025 |
2014-08-18 |
0 |
Premium* |
|
Nevro Corp |
NVRO |
SEE REMARKS, 10% Owner |
2014-11-12 |
2,194,841 |
2014-11-12 |
0 |
Premium* |
|
Tobira Therapeutics Inc |
TBRA |
10% Owner |
2016-07-13 |
1,875,905 |
2015-05-04 |
0 |
Premium* |
|
Htg Molecular Diagnostics, Inc |
HTGM |
10% Owner |
2017-08-25 |
0 |
2015-05-11 |
0 |
Premium* |
|
Colucid Pharmaceuticals, Inc. |
CLCD |
10% Owner |
2016-09-09 |
3,156,563 |
2015-05-11 |
0 |
Premium* |
|
Corvus Pharmaceuticals, Inc. |
CRVS |
10% Owner |
2020-07-08 |
1,389,498 |
2016-03-29 |
0 |
Premium* |
|
Reata Pharmaceuticals Inc |
RETA |
10% Owner |
2017-06-14 |
592,794 |
2016-06-01 |
0 |
Premium* |
|
Irhythm Technologies, Inc. |
IRTC |
10% Owner |
2016-10-25 |
2,124,448 |
|
0 |
Premium* |
|
Ra Pharmaceuticals, Inc. |
RARX |
10% Owner |
2016-10-31 |
2,031,562 |
2016-10-31 |
0 |
Premium* |
|
Kalvista Pharmaceuticals Inc |
KALV |
10% Owner |
2017-10-12 |
0 |
|
0 |
Premium* |
|
Apollo Endosurgery, Inc |
APEN |
10% Owner |
2017-07-26 |
1,301,842 |
|
0 |
Premium* |
|
Anaptysbio Inc |
ANAB |
10% Owner |
2017-08-21 |
1,936,604 |
2017-01-31 |
0 |
Premium* |
|
Entasis Therapeutics Holdings Inc. |
ETTX |
10% Owner |
2018-09-28 |
2,181,843 |
2018-09-28 |
0 |
Premium* |
|
Milestone Pharmaceuticals Inc. |
MIST |
10% Owner |
2019-05-13 |
2,674,470 |
2019-05-13 |
0 |
Premium* |
|
Morphic Holding, Inc. |
MORF |
10% Owner |
2019-06-28 |
2,645,446 |
2019-06-28 |
0 |
Premium* |
|
Mirum Pharmaceuticals, Inc. |
MIRM |
10% Owner |
2019-07-22 |
2,445,147 |
2019-07-22 |
0 |
Premium* |
|
Galera Therapeutics, Inc. |
GRTX |
10% Owner |
2021-02-18 |
2,459,021 |
2019-11-12 |
0 |
Premium* |
|
Nkarta, Inc. |
NKTX |
10% Owner |
2020-07-14 |
2,793,865 |
2020-07-14 |
0 |
Premium* |
|
Inozyme Pharma, Inc. |
INZY |
10% Owner |
2021-01-28 |
2,194,379 |
2020-07-28 |
0 |
Premium* |
|
Checkmate Pharmaceuticals, Inc. |
CMPI |
10% Owner |
2022-02-25 |
2,161,990 |
2020-08-11 |
0 |
Premium* |
|
Harmony Biosciences Holdings, Inc. |
HRMY |
10% Owner |
2020-08-21 |
3,754,973 |
2020-08-21 |
0 |
Premium* |
|
Spruce Biosciences, Inc. |
SPRB |
10% Owner |
2024-03-21 |
2,550,000 |
2020-10-14 |
0 |
Premium* |
|
Praxis Precision Medicines, Inc. |
PRAX |
10% Owner |
2020-10-20 |
2,442,080 |
2020-10-20 |
0 |
Premium* |
|
Aligos Therapeutics, Inc. |
ALGS |
10% Owner |
2020-10-20 |
2,614,563 |
2020-10-20 |
0 |
Premium* |
|
Eargo, Inc. |
EAR |
10% Owner |
2020-10-20 |
887,071 |
2020-10-20 |
0 |
Premium* |
|
Galecto Inc. |
GLTO |
10% Owner |
2020-11-02 |
2,497,791 |
2020-11-02 |
0 |
Premium* |
|
Bolt Biotherapeutics, Inc. |
BOLT |
10% Owner |
2022-07-13 |
3,703,991 |
|
0 |
Premium* |
|
Edgewise Therapeutics, Inc. |
EWTX |
10% Owner |
2022-09-14 |
6,071,703 |
2021-03-30 |
0 |
Premium* |
|
Reneo Pharmaceuticals, Inc. |
RPHM |
10% Owner |
2023-06-23 |
3,330,337 |
2021-04-13 |
0 |
Premium* |
|
Cyteir Therapeutics, Inc. |
CYT |
10% Owner |
2023-07-20 |
3,522,136 |
2021-06-22 |
0 |
Premium* |
|
Verve Therapeutics, Inc. |
VERV |
10% Owner |
2021-06-21 |
793,265 |
2021-06-21 |
0 |
Premium* |
|
Minerva Surgical Inc |
UTRS |
10% Owner |
2021-10-26 |
2,057,132 |
2021-10-26 |
0 |
Premium* |
|
Io Biotech, Inc. |
IOBT |
|
2024-07-26 |
4,354,449 |
2021-11-09 |
0 |
Premium* |
|
Arcellx, Inc. |
ACLX |
10% Owner |
2022-02-08 |
4,016,878 |
2022-02-08 |
0 |
Premium* |
|
Disc Medicine, Inc |
IRON |
10% Owner |
2023-06-28 |
1,090,772 |
|
0 |
Premium* |
|
Metagenomi, Inc. |
MGX |
10% Owner |
2024-02-13 |
1,739,175 |
2024-02-09 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
240 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 10
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
IOBT |
Io Biotech, Inc. |
10% Owner |
|
2023-08-09 |
4 |
B |
$2.03 |
$4,999,998 |
D/D |
2,469,135 |
5,707,467 |
2.45 |
- |
|
CYT |
Cyteir Therapeutics, Inc. |
10% Owner |
|
2023-06-12 |
4 |
S |
$2.06 |
$1,858 |
D/D |
(900) |
3,939,513 |
0 |
% |
|
HTGM |
Htg Molecular Diagnostics... |
10% Owner |
|
2017-08-18 |
4 |
S |
$2.10 |
$115,600 |
D/D |
(55,100) |
1,225,085 |
0 |
- |
|
CYT |
Cyteir Therapeutics, Inc. |
10% Owner |
|
2023-06-13 |
4 |
S |
$2.10 |
$5,515 |
D/D |
(2,626) |
3,936,887 |
0 |
% |
|
CYT |
Cyteir Therapeutics, Inc. |
10% Owner |
|
2023-06-14 |
4 |
S |
$2.11 |
$6,050 |
D/D |
(2,872) |
3,934,015 |
0 |
% |
|
CYT |
Cyteir Therapeutics, Inc. |
10% Owner |
|
2023-06-30 |
4 |
S |
$2.63 |
$529,288 |
D/D |
(200,937) |
3,662,636 |
0 |
% |
|
CMPI |
Checkmate Pharmaceuticals... |
10% Owner |
|
2022-02-25 |
4 |
S |
$2.70 |
$811 |
D/D |
(300) |
2,161,990 |
0 |
- |
|
CYT |
Cyteir Therapeutics, Inc. |
10% Owner |
|
2023-07-14 |
4 |
S |
$2.74 |
$30,102 |
D/D |
(11,000) |
3,651,636 |
0 |
% |
|
CYT |
Cyteir Therapeutics, Inc. |
10% Owner |
|
2023-07-17 |
4 |
S |
$2.75 |
$58,000 |
D/D |
(21,100) |
3,630,536 |
0 |
% |
|
CYT |
Cyteir Therapeutics, Inc. |
10% Owner |
|
2023-07-20 |
4 |
S |
$2.75 |
$275,140 |
D/D |
(100,000) |
3,522,136 |
0 |
% |
|
CYT |
Cyteir Therapeutics, Inc. |
10% Owner |
|
2023-07-18 |
4 |
S |
$2.76 |
$17,923 |
D/D |
(6,500) |
3,624,036 |
0 |
% |
|
CYT |
Cyteir Therapeutics, Inc. |
10% Owner |
|
2023-07-19 |
4 |
S |
$2.76 |
$5,247 |
D/D |
(1,900) |
3,622,136 |
0 |
% |
|
CMPI |
Checkmate Pharmaceuticals... |
10% Owner |
|
2022-02-24 |
4 |
S |
$2.83 |
$16,979 |
D/D |
(5,990) |
2,162,290 |
0 |
- |
|
CMPI |
Checkmate Pharmaceuticals... |
10% Owner |
|
2022-02-23 |
4 |
S |
$2.90 |
$5,277 |
D/D |
(1,820) |
2,168,280 |
0 |
- |
|
CYT |
Cyteir Therapeutics, Inc. |
10% Owner |
|
2022-07-20 |
4 |
S |
$3.00 |
$2,700,000 |
D/D |
(900,000) |
3,940,413 |
0 |
% |
|
SPRB |
Spruce Biosciences, Inc. |
10% Owner |
|
2023-02-16 |
4 |
B |
$3.17 |
$6,999,360 |
D/D |
2,208,000 |
6,722,336 |
2.45 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
10% Owner |
|
2019-07-25 |
4 |
S |
$4.00 |
$5,600,000 |
D/D |
(1,400,000) |
2,927,560 |
0 |
- |
|
ISEE |
Iveric Bio Inc |
10% Owner |
|
2016-12-15 |
4 |
S |
$4.72 |
$6,636,007 |
D/D |
(1,405,487) |
0 |
0 |
- |
|
ISEE |
Iveric Bio Inc |
10% Owner |
|
2016-12-14 |
4 |
S |
$4.97 |
$10,962,378 |
D/D |
(2,205,000) |
1,405,487 |
0 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
10% Owner |
|
2019-07-24 |
4 |
S |
$5.01 |
$266,711 |
D/D |
(53,240) |
4,327,560 |
0 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
10% Owner |
|
2020-07-07 |
4 |
S |
$5.25 |
$4,183,381 |
D/D |
(796,622) |
2,130,938 |
0 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
10% Owner |
|
2019-07-23 |
4 |
S |
$5.32 |
$211,134 |
D/D |
(39,716) |
4,380,800 |
0 |
- |
|
CRVS |
Corvus Pharmaceuticals, I... |
10% Owner |
|
2020-07-08 |
4 |
S |
$5.37 |
$3,985,166 |
D/D |
(741,440) |
1,389,498 |
0 |
- |
|
APEN |
Apollo Endosurgery, Inc |
10% Owner |
|
2017-05-11 |
4 |
S |
$5.62 |
$582,094 |
D/D |
(103,500) |
1,351,972 |
0 |
- |
|
APEN |
Apollo Endosurgery, Inc |
10% Owner |
|
2017-05-10 |
4 |
S |
$5.74 |
$8,609 |
D/D |
(1,500) |
1,455,472 |
0 |
- |
|
240 Records found
|
|
Page 4 of 10 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|